Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

Returns vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

ICICI Direct is bullish on Caplin Point Laboratories has recommended buy rating on the stock with a target price of Rs 1080 in its research report dated November 03, 2021.

Buy Caplin Point Laboratories; Target Of Rs 1080: ICICI Direct

Caplin Point Q2 Review - Stable Quarter With Strong Margins: ICICI Direct

Caplin Point Laboratories consolidated net profit rises 31.80% in the September 2021 quarter

#CNBCAwaazLive #AajKaTajaKhabar  #CaplinPoint   #aplinPointShares #BusinessNewsLive #StockMarketLive #ShareMarketLive

Caplin Point  में जानें निवेश को लेकर क्या है Experts की राय. जानें किन Levels पर करना चाहिए आपको निवेश और क्या है Target Price, देखें वीडियो.


Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

Caplin Point Share News: जानें इस Stock में Intraday के लिए रणनीति | Khiladi No. 1 | CNBC Awaaz

#CNBCAwaazLive #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive

Caplin Point पर खरीदारी देखने को मिल रही है। इस Stock में Record Highest देखने को मिल रहा है। वहीं जानें इस Stock में कहां तक के लेवल देखने को मिल सकते हैं। देखें वीडियो

Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

CAPLIN POINT Stock अपने Record Highest पर, कहां तक दिखेंगे Stock में लेवल? | CNBC Awaaz

Piramal Enterprises Ltd, Gujarat State Fertilizers & Chemicals Ltd, Caplin Point Laboratories Ltd and Patel Engineering Ltd are among the other losers in the BSE’s ‘A’ group today, 08 October 2021.

Godrej Properties Ltd leads losers in ‘A’ group

In a regulatory filing, Caplin Point Laboratories said Amaris Clinicals located at Chennai, has completed a virtual audit from United States Food and Drug Administration (USFDA) with ″nil″ observations.

Caplin Point Lab’s CRO Arm Completes USFDA Audit With ‘nil’ Observations

Caplin targets approvals on mutual recognition basis from other regulatory bodies, including ones from Latin America, a key geography for Caplin Point.

Caplin Point’s CRO Amaris Clinical completes USFDA audit with nil observations

Arvind Fashions Ltd, Caplin Point Laboratories Ltd, Jain Irrigation Systems Ltd and Usha Martin Ltd are among the other losers in the BSE’s ‘A’ group today, 14 September 2021.

Apcotex Industries Ltd leads losers in ‘A’ group

Advanced Enzyme Technologies Ltd, Caplin Point Laboratories Ltd, Hindustan Copper Ltd and Shriram City Union Finance Ltd are among the other gainers in the BSE’s ‘A’ group today, 13 September 2021.

Apcotex Industries Ltd leads gainers in ‘A’ group

Caplin Point has been buzzing in trade after it got approval from the US FDA for a hypertension drug. We speak with Vivek Siddharth, the COO of the company, to talk more about this.

#CNBCTV18 #BusinessNews #ShareMarketToday #Nifty #Sensex #CaplinPoint

CNBC-TV18 is India's No.1 Business medium and the undisputed leader in business news. The channel's benchmark coverage extends from corporate news, financial markets coverage, expert perspective on investing and management to industry verticals and beyond. CNBC-TV18 has been constantly innovating with new genres of programming that helps make business more relevant to different constituencies across India. India's most able business audience consumes CNBC-TV18 for their information & investing needs. This audience is highly diversified at one level comprising of key groups such as business leaders, professionals, retail investors, brokers and traders, intermediaries, self-employed professionals, High Net Worth individuals, students and even homemakers but shares a distinct commonality in terms of their spirit of enterprise.

For latest news and updates visit our Website: https://bit.ly/2YbpXBM
Subscribe to our Channel: https://www.youtube.com/user/CNBCTV18
Like us on Facebook: https://www.facebook.com/cnbctv18india/
Follow us on Twitter: https://twitter.com/CNBCTV18News

COO Vivek Siddharth On Caplin Point Getting US FDA Nod For Injection | Halftime Report | CNBC-TV18

Caplin Point Laboratories Limited is a pharmaceutical company. The Company's product segments include Antibiotics, Non-steroidal anti-inflammatory drugs (NSAIDS), Ophthalmics, Pain Management and Anti-ulcers.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Buy Caplin Point Laboratories; Target Of Rs 1080: ICICI Direct

Caplin Point Q2 Review - Stable Quarter With Strong Margins: ICICI Direct

Caplin Point Laboratories consolidated net profit rises 31.80% in the September 2021 quarter

News Video

Caplin Point Share News: जानें इस Stock में Intraday के लिए रणनीति | Khiladi No. 1 | CNBC Awaaz

News Video

CAPLIN POINT Stock अपने Record Highest पर, कहां तक दिखेंगे Stock में लेवल? | CNBC Awaaz

Godrej Properties Ltd leads losers in ‘A’ group

Caplin Point Lab’s CRO Arm Completes USFDA Audit With ‘nil’ Observations

Caplin Point Laboratories Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Buy Caplin Point Laboratories; Target Of Rs 1080: ICICI Direct

Caplin Point Q2 Review - Stable Quarter With Strong Margins: ICICI Direct

Caplin Point Laboratories consolidated net profit rises 31.80% in the September 2021 quarter

News Video

Caplin Point Share News: जानें इस Stock में Intraday के लिए रणनीति | Khiladi No. 1 | CNBC Awaaz

News Video

CAPLIN POINT Stock अपने Record Highest पर, कहां तक दिखेंगे Stock में लेवल? | CNBC Awaaz

Godrej Properties Ltd leads losers in ‘A’ group

Caplin Point Lab’s CRO Arm Completes USFDA Audit With ‘nil’ Observations

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock